Merck to acquire Curon Biopharmaceutical’s CN201 in strategic oncology expansion
Merck & Co., Inc. (NYSE: MRK), known as MSD outside the United States and Canada, has secured a pivotal acquisition by agreeing to purchase CN201, ... Read More
How Johnson & Johnson’s billion-dollar bet on NM26 could transform atopic dermatitis treatment
Johnson & Johnson (NYSE: JNJ) has successfully concluded its acquisition of Yellow Jersey, a division previously part of Numab Therapeutics, for a substantial $1.25 billion. ... Read More
Xencor initiates Phase 1 trial of XmAb20717 for advanced solid tumors
Xencor, a prominent biopharmaceutical company based in Monrovia, California, has recently dosed the first patient in a Phase 1 clinical trial named XmAb20717-01 (DUET-2), aimed ... Read More